Key facts
- It has raised $121.0M; the latest was Later Stage VC ($114.0M) in Jul 2024.
- Notable investors include British Business Bank, Novo Holdings, Sofinnova Partners, Brandon Capital, Abingworth — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Myricx Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Myricx Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Myricx Bio
Developer of precision medicines intended to unlock the potential of N-myristoyl transferase as a therapeutic target. The company offers novel proprietary inhibitors for humans, which result in specific cancer cell killing, focusing on targeted delivery, enhanced tumor-killing activity, bystander effects, and broad antigen expression adaptability, enabling patients to receive treatment for a wide range of diseases, including cancer and viral infections.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 13
- Website
- myricxbio.com/
- Ownership
- Privately Held (backing)
Myricx Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Myricx Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Myricx Bio in its N-PORT filings yet. We sweep new filings monthly.